(Q40533419)

5 March 2018

title

The efficacy of anti-PD-1 agents in acral and mucosal melanoma (English)

1 reference

5 March 2018

19

Jedd D Wolchok

1 reference

5 March 2018

Antoni Ribas

18

object named as

Antoni Ribas

1 reference

5 March 2018

Tara C Gangadhar

11

object named as

Tara C Gangadhar

1 reference

5 March 2018

author name string

Alexander N Shoushtari

1

1 reference

5 March 2018

Rodrigo R Munhoz

2

1 reference

5 March 2018

Deborah Kuk

3

1 reference

5 March 2018

Patrick A Ott

4

1 reference

5 March 2018

Douglas B Johnson

5

1 reference

5 March 2018

Katy K Tsai

6

1 reference

5 March 2018

Suthee Rapisuwon

7

1 reference

5 March 2018

Zeynep Eroglu

8

1 reference

5 March 2018

Ryan J Sullivan

9

1 reference

5 March 2018

Jason J Luke

10

1 reference

5 March 2018

April K S Salama

12

1 reference

5 March 2018

Varina Clark

13

1 reference

5 March 2018

Clare Burias

14

1 reference

5 March 2018

Igor Puzanov

15

1 reference

5 March 2018

Michael B Atkins

16

1 reference

5 March 2018

Alain P Algazi

17

1 reference

5 March 2018

Michael A Postow

20

1 reference

5 March 2018

language of work or name

English

0 references

publication date

17 August 2016

1 reference

5 March 2018

published in

Cancer

1 reference

5 March 2018

volume

122

1 reference

5 March 2018

issue

21

1 reference

5 March 2018

page(s)

3354-3362

1 reference

5 March 2018

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Pembrolizumab versus Ipilimumab in Advanced Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Prognostic factors of oral mucosal melanoma: histopathological analysis in a retrospective cohort of 82 cases

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

17 June 2018

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

PD-1 blockade induces responses by inhibiting adaptive immune resistance

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Genetic basis for clinical response to CTLA-4 blockade in melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Nivolumab in previously untreated melanoma without BRAF mutation

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

SF3B1 mutations are associated with alternative splicing in uveal melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Nivolumab plus ipilimumab in advanced melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

The clinical significance of tumor-infiltrating lymphocytes and microscopic satellites in acral melanoma in a korean population

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Somatic activation of KIT in distinct subtypes of melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Distinct sets of genetic alterations in melanoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Incidence of noncutaneous melanomas in the U.S.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Development of melanocyte precursors from the vertebrate neural crest.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Prognostic factors in 1,521 melanoma patients with distant metastases.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Biochemotherapy in patients with advanced head and neck mucosal melanoma

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Biochemotherapy in patients with metastatic anorectal mucosal melanoma.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134420

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

20 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.30259

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.30259

Prognosis of acral melanoma: a series of 281 patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.30259

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.30259

1 reference

5 March 2018

PMC publication ID

5134420

1 reference

5 March 2018

PubMed publication ID

27533633

1 reference

5 March 2018